Home Members Tools Credit Cards
   

RIGL Stock Quote and Technical Analysis

Portfolios Markets Resources
  Symbol List
Rigel Pharmaceuticals, Inc. (RIGL)
▼ 2.18 (-0.05) -2.24%
Open: 2.23
High: 2.31
Low: 2.03
Afterhours: N/A - N/A
Volume: 3468235
9/19/2014 4:00pm
 
Interactive Chart
EPS: -1.01 (Current Year Estimated: -1.08)
Dividend: N/A
P/E: N/A

Technicals:
52 Week Range: 2.03 - 5.00
50 Day Moving Average: 2.6363
200 Day Moving Average: 3.3272
Pivot Point (Next Trading Session): 2.17

Login or signup free to Add "RIGL" to your portfolio

Resources:

News:


RIGEL PHARMACEUTICALS INC Financials
Fri, 15 Aug 2014 17:04:35 GMT


Rigel's R348 Fails in Phase II Study, Shares Down 13.6%
Thu, 14 Aug 2014 18:30:03 GMT


Why Rigel Pharmaceuticals (RIGL) Stock Is Declining Today
Wed, 13 Aug 2014 19:37:00 GMT


Rigel eye drug fails mid-stage study, shares fall
Wed, 13 Aug 2014 14:48:52 GMT


RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Wed, 13 Aug 2014 12:00:35 GMT


Rigel experimental eye drug fails mid-stage study
Wed, 13 Aug 2014 11:44:34 GMT


R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study
Wed, 13 Aug 2014 11:30:00 GMT
[PR Newswire] - SOUTH SAN FRANCISCO, Calif., Aug. 13, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that R348, its ophthalmic JAK/SYK inhibitor, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study in patients with dry eye disease. The endpoints were measured by changes in corneal fluorescein staining, conjunctival staining, tear production and dry eye symptom scores from baseline over 12 weeks of treatment versus placebo. No significant adverse events were reported in the trial. Rigel has decided not to initiate any new studies of R348 for this indication, but is continuing its Phase 2 study of dry eye in patients with graft versus host disease (GvHD). The Company is focusing its resources on advanced clinical studies of fostamatinib in two indications. The fostamatinib programs include a recently initiated Phase 3 study in patients with immune thrombocytopenic purpura (ITP) and its planned Phase 2 study in patients with IgA Nephropathy (IgAN), an autoimmune disease of the kidneys, in Q4 2014. For more information on fostamatinib in IgAN, please visit: http://www.rigel.com/rigel/IgAN.

RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
Tue, 05 Aug 2014 20:05:33 GMT


RIGEL PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Tue, 05 Aug 2014 17:20:59 GMT


Rigel Announces Second Quarter 2014 Financial Results
Tue, 05 Aug 2014 11:30:00 GMT
[PR Newswire] - SOUTH SAN FRANCISCO, Calif., Aug. 5, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2014. For the second ...

Q2 2014 Rigel Pharmaceuticals Inc. Earnings Release - Before Market Open
Tue, 05 Aug 2014 11:07:05 GMT


Rigel Pharmaceuticals Starts Fostamatinib Late Stage Program
Thu, 17 Jul 2014 19:45:06 GMT


Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
Wed, 16 Jul 2014 12:35:00 GMT
[PR Newswire] - SOUTH SAN FRANCISCO, Calif., July 16, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura). The focus of these clinical studies is to evaluate the potential of fostamatinib to increase the platelet counts of patients with chronic ITP. Fostamatinib may provide a novel therapeutic for the underlying cause of this autoimmune disease of the blood. "Based on our extensive clinical experience with this product candidate, which includes more than 4,500 patient-years of data, we hope to demonstrate that fostamatinib can provide a new treatment option for patients with chronic ITP," said James M. Gower, chairman and chief executive officer of Rigel.

Rigel Pharmaceuticals initiates Phase 3 studies of fostamatinib in ITP
Wed, 16 Jul 2014 11:31:59 GMT


Rigel to Present at Jefferies 2014 Global Healthcare Conference
Thu, 29 May 2014 11:30:00 GMT
[PR Newswire] - SOUTH SAN FRANCISCO, Calif., May 29, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled ...

RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a V
Tue, 27 May 2014 20:16:20 GMT


RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
Wed, 07 May 2014 20:45:43 GMT


RIGEL PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Wed, 07 May 2014 17:47:55 GMT


Rigel Announces First Quarter 2014 Financial Results
Wed, 07 May 2014 11:30:00 GMT
[PR Newswire] - SOUTH SAN FRANCISCO, Calif., May 7, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2014. For the first quarter of ...

Rigel Announces Webcast of Investor Day on May 6, 2014
Wed, 30 Apr 2014 11:30:00 GMT
[PR Newswire] - SOUTH SAN FRANCISCO, Calif., April 30, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will host an Investor Day on Tuesday, May 6, 2014 from 9:30 a.m. to 12:00 ...


All Company News is Powered by Yahoo! Finance

 

 

 

Credit Cards | Finance Social Network | Credit Card Reviews | Markets
About Us | FG on the Web | Sitemap | Privacy | Terms | Contact


Copyright © 2014 Finance Globe. All rights reserved.